United States

Analyst Research Report Snapshot


Sun Pharmaceutical Industries Limited (SPIL) | Q2FY14 First Cut Analysis




IndiaNivesh Securities Pvt Ltd


13 Nov 2013





Companies referenced:


Available for Immediate Download

Sun Pharmaceutical Industries Limited (SPIL) | Q2FY14 First Cut Analysis Robust performance continues | At CMP of Rs 608, the stock is trading at P/E multiple of 26.3x of FY14E & 22.1x of FY15E earnings estimates. Our target price of Rs 644 had been achieved; we continue to have positive view on the stock. We intend to come out with detailed analysis on the stock after attending con call scheduled for today. Our rating and target price are under review.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.